External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
| العنوان: | External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry |
|---|---|
| المؤلفون: | Jimenez Fonseca, Paula, Carmona Bayonas, Alberto, Martínez Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limon Miron, Maria Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas-Izquierdo, Montserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, Gallego, Javier, On Behalf Of The Agamenon-seom Study Group |
| المساهمون: | Institut Català de la Salut, [Jimenez-Fonseca P] Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. [Carmona-Bayonas A] Medical Oncology Department, Hospital Universitario Morales Meseguer, 30007 Murcia, Spain. [Martinez-Torron A] Pharmacy Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Alsina M] Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Custodio A] Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain. [Serra O] Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Therapeutic Advances in Medical Oncology Dipòsit Digital de la UB Universidad de Barcelona r-FISABIO. Repositorio Institucional de Producción Científica instname Scientia Therapeutic Advances in Medical Oncology, Vol 13 (2021) r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| بيانات النشر: | SAGE Publications, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Stomach cancer, medicine.medical_treatment, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Other subheadings::Other subheadings::/drug therapy [Other subheadings], chemotherapy, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms [DISEASES], Esòfag - Càncer - Tractament, Quimioteràpia combinada, Capecitabine, External validity, Stomach--Cancer, Trastuzumab, Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], HER2, Quimioteràpia, medicine, external validity, Chemotherapy, Other subheadings::/therapeutic use [Other subheadings], skin and connective tissue diseases, neoplasms, RC254-282, Original Research, Cisplatin, Gastroesophageal adenocarcinoma, business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], Càncer d'estómac, gastric cancer, oxaliplatin, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oxaliplatin, Clinical trial, trastuzumab, Estómac - Càncer - Tractament, business, medicine.drug |
| الوصف: | Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1–21.0) versus ToGA regimens (7.5, 6.4–8.5), p Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX–trastuzumab in clinical practice and point toward a possible benefit of FOLFOX–trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials. |
| وصف الملف: | application/pdf; image/jpeg |
| اللغة: | English |
| تدمد: | 1758-8359 1758-8340 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8882f2f942a7f552c34340000811102Test http://europepmc.org/articles/PMC8216357Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b8882f2f942a7f552c34340000811102 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17588359 17588340 |
|---|